dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· June 29, 2026

Q1 Earnings Highs And Lows: The Marzetti Company (NASDAQ:MZTI) Vs The Rest Of The Shelf-Stable Food Stocks

View original at finance.yahoo.com
Q1 Earnings Highs And Lows: The Marzetti Company (NASDAQ:MZTI) Vs The Rest Of The Shelf-Stable Food Stocks Q1 Earnings Highs And Lows: The Marzetti Company (NASDAQ:MZTI) Vs The Rest Of The Shelf-Stable Food Stocks As the Q1 earnings season wraps, let's dig into this quarter's best and worst performers in the shelf-stab…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • As a group, the 17 shelf-stable food stocks reported revenues in line with analyst consensus estimates for Q1, while next quarter revenue guidance was 11.6% below consensus.

    60% confidence
  • Sister Schubert's dinner roll sales benefited from pull-forward of demand due to the earlier Easter holiday.

    60% confidence
  • Retail segment gains were more than offset by category softness and reduced sales into the club channel.

    60% confidence
  • Marzetti reported record-high gross profit in Q1 despite the decline in net sales.

    60% confidence
  • New York Bakery frozen garlic bread products continued to grow sales and increase market share in the Retail segment.

    60% confidence
  • Foodservice reported net sales increased 1.5% and Adjusted Foodservice Net Sales (excluding non-core TSA sales) grew 1.8%, led by higher demand from core national chain restaurant accounts.

    60% confidence
  • Shelf-stable food stocks have collectively declined; average share prices are down 3.2% since the latest earnings results.

    60% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,995
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,995 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com